Core Viewpoint - The company, Chutian Technology, is focusing on the development of pharmaceutical robots that align with the core pharmaceutical equipment industry chain, aiming for automation and intelligence in pharmaceutical production [1] Summary by Relevant Categories Business Strategy - The company is concentrating on the clean medical core sector to promote the upgrade of pharmaceutical equipment towards unmanned and intelligent solutions, which aligns with future trends in pharmaceutical production [1] Product Development - Chutian Technology has successfully developed and implemented clean robots and sorting robots, which are adaptable to existing business scenarios [1] Competitive Advantage - The company's core competitive advantages lie in two areas: a deep understanding of the application scenarios of its business segments and a profound comprehension of the production processes in the downstream pharmaceutical industry, enabling precise matching of current pharmaceutical equipment needs [1]

Report Summary 1. Report Industry Investment Rating - Not provided in the content 2. Core View of the Report - The company achieved a significant turnaround in net profit and net profit after non-recurring items in 2025 compared to 2024, mainly due to increased international market expansion, a product differentiation strategy, cost reduction and efficiency improvement measures, and refined management [22]. - The company's performance improvement in 2025 is mainly based on its long - term product and manufacturing technology accumulation, enhanced overall solution capabilities and globalization service capabilities, as well as timely strategic adjustments in 2024 [23]. 3. Summary by Relevant Catalogs 3.1 Research Basic Situation - Research object: Chutian Technology [17] - Industry: Medical devices [17] - Reception time: 2026 - 01 - 26 [17] - Listed company reception staff: Board Secretary Huang Yuting, Securities Affairs Representative Zhou Dewei [17] 3.2 Detailed Research Institutions - Reception object type: Securities company - Institution: China Merchants Securities - Number of related personnel: 2 [20] 3.3 Research Institution Proportion - Not detailed in the content 3.4 Main Content Data 3.4.1 Reasons for the Company's Profit Improvement in 2025 - Increased international market expansion: In 2025, overseas business entered a rapid growth channel, with breakthroughs in Southeast Asia, the Middle East and Africa, and the Americas. The proportion of international business in the company's overall business increased significantly, driving profit growth [22]. - Product differentiation and cost - reduction: Since the second half of 2024, the company adopted a product differentiation strategy to improve order quality and carried out a series of cost - reduction and efficiency - improvement measures, which significantly increased the gross profit margin [22]. - Refined management: Since the second half of 2024, the company carried out refined management measures, and the overall operating cost in 2025 was effectively controlled, with a significant decrease in total period expenses compared to the same period in 2024 [22]. 3.4.2 Industry Trends - Domestic industry competition is still fierce but gradually easing, with characteristics such as accelerated domestic substitution, increased market concentration, expanded advantages of leading enterprises, and international market expansion becoming a new growth point [23]. - The focus of industry competition has shifted from traditional equipment performance to technological integration, system solutions, and global service capabilities [23]. 3.4.3 Overseas Export in 2025 - The company's international sales and service system team has been growing, with local sales and service outlets established in more than 20 key countries and regions. It focuses on five major regions and promotes high - quality sales and services [23]. - The export orders in 2025 increased compared to 2024 [23]. 3.4.4 Pharmaceutical Robot Layout - The company's pharmaceutical robot business layout focuses on the core pharmaceutical equipment industry chain and the medical clean core sector, aiming to upgrade pharmaceutical equipment to unmanned and intelligent levels [23]. - The company has achieved self - production and product implementation of clean robots and sorting robots, which can effectively meet the needs of existing business scenarios [24]. - The core competitive advantages are a deep understanding of application scenarios and downstream pharmaceutical production processes, which can help product iteration and efficiency improvement [24]. 3.4.5 Operating Conditions of ROMACO - ROMACO Group's operating conditions have improved steadily compared to 2024, and its core business indicators and market competitiveness have increased [24]. - Whether goodwill will be impaired and the impairment amount need to be based on formal reports from third - party asset appraisal companies and audit institutions [24]. 3.4.6 New Product Development - The company has been insisting on technological innovation, with a high R & D investment proportion in the industry. It has continuously launched new products and technologies in recent years [25]. - Future products include continuous BFS, fully automatic intelligent lamp inspection machines, etc. The company will continue to implement the "dual - priority" strategy of product and manufacturing technology [25]. 3.4.7 Business Outlook in 2026 - In the business aspect, the company will continue to expand overseas markets, promote the globalization strategy, and increase the proportion of international business in revenue. It will also focus on innovation to drive the integration of the pharmaceutical equipment industry chain with the international market [25]. - In the management aspect, the company will continue to implement "quality improvement and efficiency enhancement", using technological means and management measures to achieve cost reduction and efficiency improvement [25].

Financial Performance - In the first nine months of 2025, the company achieved revenue of 3.896 billion CNY, a decrease of 6.6% compared to the same period last year [2] - Net profit attributable to shareholders was 84 million CNY, an increase of 145.11% year-on-year [2] - The third quarter of 2025 saw revenue of 1.479 billion CNY, a year-on-year increase of 10.17%, with net profit rising to 93 million CNY, up 186.19% [2] Strategic Initiatives - The company implemented three core strategies leading to profit growth: 1. Focus on "quality improvement and efficiency enhancement" in domestic operations, leading to significant optimization of profit quality [2] 2. Accelerated international business expansion, with international revenue from domestic subsidiaries significantly increasing [2] 3. Deep implementation of cost reduction and efficiency enhancement strategies, resulting in improved operational efficiency and reduced personnel costs [2][3] International Market Expansion - The company is focusing on five key regions for international market expansion: Southeast Asia, Middle East and Africa, Europe, Americas, and India/Australia [3] - The overseas business has entered a rapid growth phase, with notable breakthroughs in the Middle East, Africa, and Southeast Asia [3] Product Development and Market Position - The company is actively developing its biopharmaceutical consumables business, focusing on three main categories, with significant orders already secured [3] - The pharmaceutical robotics business is aligned with the core pharmaceutical equipment industry, aiming for automation and intelligence upgrades [4] Market Competition and Profitability Outlook - The domestic market remains competitive but is becoming more rational, with a focus on differentiated competition [4] - The company expects a gross profit margin of around 30% for 2025, with potential for steady improvement through high-quality development and cost reduction measures [4]